Jonathan Miller
Stock Analyst at Evercore ISI Group
(0.43)
# 4,294
Out of 5,241 analysts
10
Total ratings
33.33%
Success rate
-21.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Outperform | $33 → $48 | $24.43 | +96.48% | 1 | Mar 9, 2026 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $11 → $13 | $2.07 | +528.02% | 1 | Mar 9, 2026 | |
| AVIR Atea Pharmaceuticals | Maintains: Outperform | $6 → $10 | $4.14 | +141.55% | 1 | Mar 9, 2026 | |
| ARVN Arvinas | Maintains: Outperform | $14 → $19 | $8.78 | +116.40% | 1 | Feb 25, 2026 | |
| AURA Aura Biosciences | Reinstates: Outperform | $13 | $7.47 | +74.03% | 1 | Nov 26, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: In-Line | $17 → $8 | $12.69 | -36.96% | 1 | Nov 11, 2025 | |
| PROK ProKidney | Initiates: Outperform | n/a | $1.61 | - | 1 | Sep 2, 2022 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | n/a | $5.89 | - | 1 | Nov 24, 2021 | |
| STTK Shattuck Labs | Initiates: Outperform | n/a | $5.97 | - | 1 | Jan 11, 2021 | |
| NBTX Nanobiotix | Initiates: Outperform | n/a | $49.47 | - | 1 | Jan 6, 2021 |
Zymeworks
Mar 9, 2026
Maintains: Outperform
Price Target: $33 → $48
Current: $24.43
Upside: +96.48%
Caribou Biosciences
Mar 9, 2026
Maintains: Outperform
Price Target: $11 → $13
Current: $2.07
Upside: +528.02%
Atea Pharmaceuticals
Mar 9, 2026
Maintains: Outperform
Price Target: $6 → $10
Current: $4.14
Upside: +141.55%
Arvinas
Feb 25, 2026
Maintains: Outperform
Price Target: $14 → $19
Current: $8.78
Upside: +116.40%
Aura Biosciences
Nov 26, 2025
Reinstates: Outperform
Price Target: $13
Current: $7.47
Upside: +74.03%
Intellia Therapeutics
Nov 11, 2025
Downgrades: In-Line
Price Target: $17 → $8
Current: $12.69
Upside: -36.96%
ProKidney
Sep 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.61
Upside: -
Entrada Therapeutics
Nov 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.89
Upside: -
Shattuck Labs
Jan 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.97
Upside: -
Nanobiotix
Jan 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $49.47
Upside: -